Novel antidepressant drugs, arterial hypertension and cardiovascular disease

Recent Pat Cardiovasc Drug Discov. 2013 Dec;8(3):178-85. doi: 10.2174/1574890109666140407154738.

Abstract

Depression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. The purpose of the present article is to review the impact of novel antidepressant patent drugs on cardiovascular disease and arterial hypertension.

Publication types

  • Review

MeSH terms

  • Animals
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / therapeutic use*
  • Bupropion / adverse effects
  • Bupropion / therapeutic use
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / physiopathology*
  • Cardiovascular System / drug effects
  • Cyclohexanols / adverse effects
  • Cyclohexanols / therapeutic use
  • Humans
  • Hypertension / chemically induced
  • Hypertension / physiopathology*
  • Patents as Topic
  • Selective Serotonin Reuptake Inhibitors / adverse effects
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Venlafaxine Hydrochloride

Substances

  • Antidepressive Agents
  • Cyclohexanols
  • Serotonin Uptake Inhibitors
  • Bupropion
  • Venlafaxine Hydrochloride